Previous Article | Next Article 
Journal of Virology, April 1999, p. 2694-2702, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
I
B-Mediated Inhibition of Virus-Induced Beta
Interferon Transcription
Michèle
Algarté,1,2
Hannah
Nguyen,1,3
Christophe
Heylbroeck,1,3
Rongtuan
Lin,1,2 and
John
Hiscott1,2,3,*
Terry Fox Molecular Oncology Group, Lady
Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish
General Hospital,1 and Departments of
Microbiology3 and
Medicine,2 McGill University, Montreal,
Quebec, Canada H3T 1E2
Received 2 September 1998/Accepted 10 December 1998
 |
ABSTRACT |
We have examined the consequences of overexpression of the I
B
and I
B
inhibitory proteins on the regulation of NF-
B-dependent beta interferon (IFN-
) gene transcription in human cells after Sendai virus infection. In transient coexpression studies or in cell
lines engineered to express different forms of I
B under tetracycline-inducible control, the IFN-
promoter (
281 to +19) linked to the chloramphenicol acetyltransferase reporter gene was
differentially inhibited in response to virus infection. I
B
exhibited a strong inhibitory effect on virus-induced IFN-
expression, whereas I
B
exerted an inhibitory effect only at a
high concentration. Despite activation of the I
B kinase complex by
Sendai virus infection, overexpression of the double-point-mutated
(S32A/S36A) dominant repressors of I
B
(TD-I
B
) completely
blocked IFN-
gene activation by Sendai virus. Endogenous IFN-
RNA
production was also inhibited in Tet-inducible TD-I
B
-expressing
cells. Inhibition of IFN-
expression directly correlated with a
reduction in the binding of NF-
B (p50-RelA) complex to PRDII after
Sendai virus infection in I
B
-expressing cells, whereas IFN-
expression and NF-
B binding were only slightly reduced in
I
B
-expressing cells. These experiments demonstrate a major role
for I
B
in the regulation of NF-
B-induced IFN-
gene
activation and a minor role for I
B
in the activation process.
 |
INTRODUCTION |
Human interferons (IFNs) are
synthesized by leukocytes, macrophages, and epithelial cells in
response to virus infection and other pathogenic stimuli. IFNs induce a
group of genes encoding proteins with a broad range of antiviral,
immunoregulatory, and growth-suppressive activities (reviewed in
reference 47). The regulation of alpha/beta IFN
(IFN-
and IFN-
) transcription has served as an important model
for examining the transcriptional mechanisms controlling
virus-inducible gene expression (reviewed in reference
20). IFN-
transcriptional regulation is
controlled by the protein-DNA interactions within 110 nucleotides
upstream of the intronless structural gene and consisting of multiple
overlapping positive and negative regulatory domains. Four positive
regulatory domains bind specific members of the NF-
B, IRF, and
CREB/ATF transcription factors, as well as the chromatin-associated
HMGI(Y) proteins in an induction-specific and cooperative manner; a
higher-order structure termed the enhanceosome is formed that, via
recruitment of the CBP/p300 coactivator, stimulates IFN-
gene
transcription (29). Recently, it has been demonstrated that
in cells infected by virus, the newly identified IRF-3 and IRF-7
factors bind to the IFN-
promoter, together with NF-
B and
ATF-2/c-Jun. The association of these factors in the IFN-
enhanceosome is thought to create a new protein-protein interface that
interacts with the transcriptional coactivator CBP/p300 proteins in
response to virus infection, leading to virus-mediated gene activation
(16, 24, 26a, 29, 40, 48).
The PRDII domain (
64 to
55) contains the consensus site
5'-GGGAAATTCC-3' for the binding of NF-
B/Rel
transcription factors. Heterodimer or homodimer combinations of NF-
B
play an important role in the regulation of a large variety of genes,
including cytokines, immune regulatory genes, receptors, and early
genes of several viruses. NF-
B binding activity is inducible in most cell types by viruses, double-stranded RNA, cytokines, phorbol esters,
and oxygen radicals. NF-
B was initially described as a protein
complex composed of two subunits (p50 and p65) retained in the
cytoplasm by its association with the inhibitor subunits I
B.
Induction resulted in the release of the heterodimer p50-p65 by I
B,
translocation to the nucleus, and binding to
B sites. The DNA
binding NF-
B and the inhibitory I
B proteins are composed of
multiple family members that contribute to the diversity of NF-
B-mediated gene regulation (reviewed in references 2, 3, 27, and 46).
Phosphorylation and degradation of I
B are crucial regulatory events
in the activation of NF-
B DNA binding activity. After inducer-mediated stimulation I
B
is phosphorylated within the N-terminal signal response domain at Ser-32 and Ser-36 (6, 7,
43) by the I
B kinase (IKK) (13, 28, 35, 50, 53), ubiquitinated, and subsequently degraded by the 26S proteasome (1,
9, 37). Substitution of Ser-32 and Ser-36 prevents I
B
phosphorylation, ubiquitination, and degradation, thus generating nondegrading, transdominant repressors of I
B
(6, 8,
42). The C-terminal PEST domain of I
B
is involved in the
intrinsic stability of the protein, and this region is constitutively
phosphorylated by CKII (26, 38).
The inducibility of NF-
B is controlled by different I
B proteins,
thus providing an additional level of regulation for NF-
B-dependent gene transcription. Two well-characterized forms, I
B
and I
B
(44, 49), share several common structural features,
including conserved N-terminal signal response, ankyrin repeat, and
C-terminal PEST domains. However, I
B
and I
B
respond
differentially to distinct inducers: the level of I
B
is not
affected by tumor necrosis factor alpha (TNF-
) or phorbol myristate
acetate and, after lipopolysac- charide or interleukin-1 (IL-1)
induction, the degradation and resynthesis of I
B
occurs more
slowly than I
B
(41). I
B
is also resynthesized in
stimulated cells as a hypophosphorylated protein which is able to form
stable complexes with NF-
B in the cytosol (32, 49);
however, this interaction fails to mask the nuclear localization
sequence and DNA binding domain of NF-
B, resulting in
NF-
B-I
B
complexes in the nucleus. This hypophosphorylated form
of I
B
acts as a chaperone, by protecting NF-
B from I
B
and permitting a prolonged activation of gene transcription by
NF-
B (39). A model has been proposed for NF-
B activation consisting of two overlapping phases: first, a
transient phase mediated mainly through I
B
and, second, a
persistent phase of activation mediated by I
B
(39,
41). Recently, two different isoforms of I
B
, I
B
1 (43 kDa) and I
B
2 (41 kDa), generated as a consequence of RNA
processing and differing in their C-terminal PEST domains, have been
identified. The relative amounts of these two forms and their
degradation in response to stimulation appears to be cell-type
specific. Both I
B
1 and I
B
2 bind to the same NF-
B
subunits and are constitutively phosphorylated (19).
Furthermore, I
B
is a stronger inhibitor of NF-
B activity than
I
B
; the inhibitory activity of I
B
is facilitated on
promoters containing HMGI(Y) binding regions (44).
In the present study, the consequences of overexpression of the
I
B
and I
B
inhibitory proteins on the regulation of
NF-
B-dependent IFN-
gene transcription after Sendai virus
infection was examined. In transient coexpression studies and in stable
tetracycline-inducible human 293 cells, wild-type I
B
decreased
IFN-
promoter activity, whereas I
B forms with the S32/36A point
mutations completely abolished IFN-
gene expression. I
B
overexpression had minimal effects on IFN-
promoter activity.
Analysis of NF-
B protein-DNA complexes in I
B-expressing cells
revealed quantitative and temporal alterations in the patterns of
NF-
B binding to the PRDII domain after Sendai virus infection. These
studies demonstrate differential regulation of IFN-
transcription by
I
B
and I
B
and indicate a major role for I
B
but not
I
B
in IFN-
regulation.
 |
MATERIALS AND METHODS |
Generation of plasmids.
For transient transfections,
wild-type human I
B
(wtI
B
) or mutated human I
B
cDNA
was inserted downstream of the simian virus 40 promoter in the pSVK3
vector (Pharmacia Biotech, Uppsala, Sweden) (5). cDNA
encoding I
B
(a kind gift from Dimitris Thanos) was inserted into
SVK3 between the sites EcoRI and XhoI. Mutated
human I
B
cDNA was generated as previously described (26). In I
B
(2N), serine 32 and serine 36 are replaced
by alanine; in I
B
(3C) serine 283, threonine 291, and threonine 299 were substituted by an alanine residue, and in I
B
-
4 22 amino acids were deleted from the terminal end. 2N+3C and 2N
4 were
combinations of the above plasmids. Constructs for the establishment of
stable cell line CMVt-rtTA, CMVt-wtI
B
, and I
B
mutants were generated as previously described (5, 25). cDNA encoding I
B
(a kind gift of D. Thanos) was inserted into pCMVt-neo vector (4) at the NotI site.
Cell culture and generation of I
B cell lines.
Human 293 cells were cultured in alpha Dulbecco modified Eagle medium (alpha-MEM)
supplemented with 10% heat-inactivated fetal bovine serum, glutamine,
and antibiotics. CMVt-rtTA 293 cells (26) were cultured in
the same medium containing 2.5 ng of puromycin (Sigma) per µl.
CMVt-based plasmids (25) expressing wtI
B
, I
B
mutants, or I
B
were introduced into CMVt-rtTA 293 cells by the
calcium phosphate coprecipitation method. Cells were selected at
48 h after transfection in alpha-MEM supplemented with 10% heat-inactivated fetal bovine serum, glutamine, and the antibiotics puromycin (2.5 ng/µl) and G418 (400 µg/ml) (Life Technologies, Inc.). Cell clones resistant to G418 were selected individually after
I
B expression levels induced by 1 µg of doxycycline (Dox; Sigma)
per ml were examined.
Transfections and CAT reporter gene assays.
Subconfluent 293 cells, CMVt-rtTA 293 cells, or CMVt-rtTA-I
B-expressing 293 cells
were transfected with the IFN-
-CAT reporter plasmid, by the calcium
phosphate coprecipitation method (17). All of the
transfections contained equivalent amounts of DNA standardized with the
CMV-B1 vector. In some experiments, cells were infected with Sendai
virus (500 hemagglutinating units [HAU]/ml for 90 min). At 24 h
after infection (48 h after transfection), cytoplasmic extracts were
prepared and the protein concentration was determined by Bradford assay
(Bio-Rad). Then, 100 µg of cytoplasmic protein extract was assayed
for 2 to 4 h at 37°C as previously described (17).
Relative chloramphenicol acetyltransferase (CAT) activity was
quantified by scintillation counting of acetylated and nonacetylated chloramphenicol forms.
Western blot analysis.
To characterize I
B expression,
wtI
B
and I
B
mutants and I
B
-expressing cells were
cultured in the presence of Dox for various times. Cells were washed
twice with phosphate-buffered saline (PBS) and resuspended in lysis
buffer containing 10 mM Tris-Cl (pH 8.0), 60 mM KCl, 1 mM EDTA, 1 mM
dithiothreitol (DTT), 0.5% Nonidet P-40, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), and 10 µg of pepstatin, 10 µg of leupeptin, and 10 µg of aprotinin per ml. Whole-cell extracts (20 µg) were resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
in a 10% gel. Proteins were transferred to Hybond transfer membrane
(Amersham, Cleveland, Ohio). Membrane was blocked in a 5% milk-PBS
solution for 1 h at room temperature and probed with anti-I
B
(22) or anti-I
B
G-20 against the N-terminal sequences
of I
B
1 and I
B
2 (Santa Cruz Biotechnology, Inc., Valencia,
Calif.) antibody in 5% milk-PBS at a dilution of 1:1,000 overnight at
4°C. Membranes were washed four times with PBS, incubated with
peroxidase-conjugated secondary antibodies (KPL, Gaithersburg, Md.)
(goat anti-mouse antibody was used to detect I
B
, and goat
anti-rabbit antibody was used to detect I
B
, each at a dilution of
1:1,000), and visualized with the chemiluminescence detection system as
recommended by the manufacturer (NEN-Life Science, Boston, Mass.).
Immunoprecipitation and kinase assay.
For the in vitro
kinase assay, cells were left untreated, were treated with TNF-
(10 ng/ml) for 10 min, or were infected with Sendai virus (80 HAU/ml) for
different times as indicated. Cells were washed twice in cold PBS and
resuspended in lysis buffer containing 20 mM Tris-Cl (pH 7.5), 200 mM
NaCl, 0.5% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM NaF, 0.5 mM
PMSF, and 5 µg of leupeptin, 5 µg of pepstatin, and 5 µg of
aprotinin per ml. Whole-cell extracts (200 µg) were incubated with
500 ng of anti-IKK
antibody H-744 (Santa Cruz) and 30 µl of
protein A-Sepharose beads for 2 to 4 h at 4°C. Beads were washed
three times with lysis buffer and two times with kinase buffer (50 mM
Tris-Cl, pH 8.0; 100 mM NaCl; 2 mM MgCl2; 1 mM sodium
orthovanadate; 1 mM NaF; 20 mM
-glycerophosphate; 1 mM DTT; 0.5 mM
PMSF; 5 µg [each] of leupeptin, pepstatin, and aprotinin per ml)
and then incubated at 30°C for 30 min in kinase buffer
containing 5 µCi of [
-32P]ATP and 2 µg of
recombinant GST-I
B
(amino acids [aa] 1-55) or GST-I
B
(aa
1 to 55; S32/36A). Reactions were subjected to SDS-PAGE in a 12%
polyacrylamide gel. The gels were dried and subjected to autoradiography.
RNA preparation and RNase protection assay.
Total RNA from
293 cells was extracted with the RNeasy Mini-Kit (Qiagen, Valencia,
Calif.). Total RNA (5 µg) was subjected to RNase protection analysis
by using a human CK3 cytokine multi-probe template set of the RiboQuant
Multi-Probe RPA kit (PharMingen, San Diego, Calif.). Labelled fragments
protected from RNase digestion and corresponding to IFN-
mRNA were
quantified with the NIH Image 1.60 software package. Values were
normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
L32 (housekeeping gene) mRNA levels and then plotted as IFN-
/GAPDH
mRNA ratios. Similar results were obtained in three independent experiments.
Electrophoretic mobility shift assay.
Nuclear extracts were
prepared as previously described (17). First, 5 µg of
nuclear extracts was incubated with 5 µg of poly(dI-dC) (Pharmacia)
for 10 min at room temperature in a total volume of nuclear extract
buffer containing 0.1% Nonidet P-40. Then, each sample was incubated
for 30 min at room temperature in the presence of 100,000 cpm of
[
-32P]ATP-labeled oligonucleotide probe corresponding
to the PRDII domain of the IFN-
promoter
(5'-GGGAAATTCCGGGAAATTCC-3'). Protein DNA complexes were
then separated on a 5% native polyacrylamide gel (60:1 cross-link) in
0.2× TBE. In competition analysis, a 200-fold molar excess of
unlabelled oligonucleotide was incubated in the presence of poly(dI-dC)
with the nuclear extracts for 30 min before the addition of probe to
the extracts. To examine the individual proteins present in the
complex, polyclonal subunit-specific antisera against NF-
B were used
as previously described (17).
 |
RESULTS |
Inhibition of IFN-
promoter activity by I
B
overexpression.
To examine the effect of I
B
and I
B
on
IFN-
promoter activity, 293 cells were cotransfected with a CAT
reporter gene driven by the entire IFN-
promoter from
281 to +19
and different expression plasmids encoding wild-type or mutated
I
B
and wild-type I
B
(Fig.
1A). Several mutant forms of I
B
were examined: I
B
-2N, which contains the S32A/S36A double point
mutation; I
B
-3C, which contains the S283A/T291A/T299A triple
point mutation; I
B
-
4, which contains a 22-aa deletion in the
PEST C-terminal domain; and the combination mutants I
B
-2N+3C and
I
B
-2N+
4. At 24 h posttransfection the cells were infected
with Sendai virus (500 HAU/ml), and 24 h later the cells were
lysed and submitted to CAT reporter gene assay. Full activation of the
IFN-
promoter corresponding to a 50- to 100-fold stimulation was
observed in Sendai virus-infected cells cotransfected with the IFN-
CAT plasmid (Fig. 1B). Cotransfection of increasing amounts of
wtI
B
expressing plasmid resulted in a concentration-dependent
decrease of IFN-
promoter activity. IFN-
promoter activity was
partially inhibited at low wtI
B
concentrations (I
B
/IFN-
ratio = 0.25) and completely inhibited at higher levels of
wtI
B
(I
B
/IFN-
ratio = 4). I
B
mutants
containing the S32A/S36A point mutations (I
B
2N, -2N+
4, and
-2N+3C) were strongly inhibitory and almost completely inhibited IFN-
promoter activity at the I
B
/IFN-
ratio of 0.25. In
contrast, overexpression of I
B
was a weak inhibitor of IFN-
promoter activity, with a less-than-twofold inhibition of IFN-
activity at a I
B
/IFN-
ratio of 4.0; complete inhibition of
IFN-
promoter activity was observed at the I
B
/IFN-
ratio of
8. These initial experiments established that I
B
was a stronger
inhibitor of IFN-
gene expression than I
B
; furthermore the
nondegrading transdominant forms of I
B
(TD-I
B
) are at least
10-fold more inhibitory than wtI
B
.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Schematic of I B protein. Mutations of I B
are as indicated: I B -2N, which contains the S32A/S36A double
point mutation; I B -3C, which contains the S283A/T291A/T299A
triple point mutation; I B - 4, which contains a 22-aa deletion
in the PEST C-terminal domain; and the combination mutants
I B -2N+3C and I B -2N+ 4. (B) I B expression inhibits
IFN- gene expression. The IFN- -CAT reporter plasmid (2.5 µg)
was cotransfected together with I B expression plasmids into 293 cells by the calcium phosphate method. After 24 h the cells were
infected by Sendai virus (500 HAU/ml), and after a further 24 h
the cells were harvested and assayed for CAT activity by using
cytoplasmic extracts (50 to 100 µg for 2 h). The ratio of I B
to IFN- -CAT reporter is indicated on the graph. The relative CAT
activity is expressed as a percentage of the activity observed after
Sendai virus infection with IFN- -CAT reporter in the absence of
I B plasmid.
|
|
Establishment of human 293 cells inducibly expressing I
B
and
I
B
transgenes.
Human 293 cells constitutively expressing
Dox-inducible, reverse-tetracycline-inducible transactivator (rtTA-293)
were generated as previously described (25); in a second
selection, rtTA-293 cells were established that inducibly expressed
wtI
B
, mutant I
B
(-2N, -3C, -2N+3C, -
4, and -2N
4) and
wtI
B
(Fig. 2). For each construct,
10 to 20 potential clones were expanded individually and screened by
immunoblot for protein expression after Dox addition for 48 h. For
each I
B construct, at least three inducible clones were selected and
utilized for further studies; a representative clone expressing each
construct is analyzed for Dox inducibility (Fig. 2A). Clones were also
selected for their ability to grow at approximately the same rate as
parental 293 cells, since overexpression of different I
Bs decreased
cell growth and in some clones induced apoptotic cell death
(12). Most clones displayed basal I
B expression prior to
Dox addition, detected with the MAD3 antibody (Fig. 2A, lanes 3, 5, 7, 9, 11, and 13) and displayed Dox-inducible transgene expression (Fig.
2A, lanes 4, 6, 8, 10, 12, and 14). I
B
-expressing cells also
displayed basal levels of transgene expression (Fig. 2C, lanes 3 and
4).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
Dox-inducible expression of I B in rtTA-293 cells. (A)
Cells selected for wtI B or TD-I B expression were induced
with Dox for 48 h (+) or not induced ( ). (B) Immunoblot analysis
of I B -2N+3C expression after Dox induction for 0 to 96 h.
(C) I B induced expression by Dox for 48 h (+) or not induced
( ). Whole-cell extract (20 µg) prepared from induced or uninduced
rtTA-293-, wtI B -, I B -2N-, I B -2N+3C-,
I B -2N 4-, and I B -expressing cells were subjected to
SDS-PAGE and transferred to nitrocellulose membrane. WtI B and
I B mutants were detected with I B -MAD3-specific antibody
(33), and wtI B was detected with I B -specific
antibody (Santa Cruz Biotechnology).
|
|
The kinetics of I

B transgene induction were characterized at various
times after Dox induction, and a representative analysis
is shown for
the I

B

-2N+3C clone (Fig.
2B). This clone possessed
basal
transgene expression compared to control rtTA-293 cells
(compare Fig.
2B, lanes 1 to 3). Between 1 and 3 h after Dox addition,
the level
of I

B

transgene expression increased (Fig.
2B, lanes
3 to 5) and
reached a peak at about 12 h after Dox addition; high-level
expression remained constant for 96 h postinduction (Fig.
2B,
lanes 8 to 11). Each selected cell line possessed a similar expression
pattern; I

B

transgene expression was detectable before Dox
induction
but increased strongly and progressively following Dox
treatment
(Fig.
2B). In subsequent experiments, Dox was added 48 h
before
Sendai virus
infection.
Virus-induced activation of the IKK complex.
To examine the
kinetics of Sendai virus-induced activation in 293 cells, the induction
of I
B
phosphorylation by the IKK complex was first examined.
Sendai virus infection led to activation of the IKK complex as
demonstrated by an in vitro kinase assay with immunoprecipitated IKK
and the I
B
(aa 1 to 55) protein as substrate; activation of IKK
by Sendai virus was similar to the level of activated IKK observed
after TNF-
stimulation of 293 cells (Fig. 3A, lanes 1 to 3). No
phosphorylation was observed when the I
B
(aa 1 to 55; S32/36A)
substrate was used (Fig. 3A, lanes 4 to
6) indicating the specificity of IKK phosphorylation. The kinetics of
virus-induced IKK activation demonstrated that IKK activity was maximal
at 3 and 6 h after infection (Fig. 3B, lanes 1 to 4) and
subsequently decreased between 9 and 15 h (Fig. 3B, lanes 5 to 7).
The kinetics of IKK induction also correlated directly with the
phosphorylation and degradation of I
B
in virus-infected 293 cells
(Fig. 3C). Beginning at 3 h postinfection, a slower-migrating form
of phosphorylated I
B
was detected (Fig. 3C, lane 3), while at
6 h the phosphorylated form was detected but the amount of I
B
decreased by fourfold, reflecting phosphorylation-dependent degradation of I
B
(Fig. 3C, lane 4). This kinetic analysis
demonstrates that Sendai virus infection of 293 cells leads to
activation of the IKK complex and phosphorylation of I
B
.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Activation of the I B kinase complex by Sendai virus
infection. (A) Strain 293 cells were either left untreated (lanes 1 and
4), treated with TNF- (10 ng/ml) for 10 min (lanes 2 and 5), or
infected with Sendai virus (80 HAU/ml) for 8 h (lanes 3 and 6).
The I B kinase complex was immunoprecipitated from whole-cell
extracts (200 µg) with the anti-IKK antibody H-744 (Santa Cruz)
and assayed for I B phosphorylation by using recombinant wild-type
GST-I B (aa 1 to 55) (lanes 1 to 3) or mutant GST-I B (aa 1 to 55; S32/36A) substrate (lanes 4 to 6). (B) Kinetic analysis of I B
kinase activation after Sendai virus infection. Strain 293 cells were
infected with Sendai virus for different times as indicated, and the
kinase activity was measured as described above. (C) Phosphorylation
and degradation of I B in response to Sendai virus infection.
Whole-cell extracts (20 µg) from 293 cells infected with Sendai virus
(80 HAU/ml) for different times as indicated were subjected to SDS-PAGE
and transferred to nitrocellulose membrane. I B was detected with
a monoclonal anti-I B antibody. The positions of I B and
phosphorylated I B are indicated by the arrows.
|
|
Detection of IFN-
synthesis in I
B-expressing cells.
To
examine IFN-
inducibility in I
B-expressing cells, total RNA from
normal and Sendai virus-infected cells was examined by RNase protection
analysis at different times after infection, either with or without Dox
addition to increase the level of I
B transgene expression (Fig.
4). In control rtTA-293 cells with or
without Dox addition, Sendai virus induced IFN-
mRNA initially at
6 h (Fig. 4A, lanes 1 to 3 and lanes 8 to 10); the amount of mRNA
reached a peak at 12 h and thereafter decreased by 24 h (Fig. 4A, lanes 4 to 7 and lanes 11 to 14). In wtI
B
-expressing cells, the induced level of IFN-
was delayed slightly, since only a low
level of IFN-
mRNA was detected at 6 h, but again IFN-
mRNA reached a peak of expression at 12 h (Fig. 4B, lanes 1 to 7); the
virus-induced level of IFN-
mRNA in wtI
B-expressing cells was not
significantly reduced compared to rtTA-expressing cells (compare Fig.
4A and B, lanes 3 to 5, and Fig. 5A and
B). Dox induction of the wtI
B
transgene reduced the maximum level
of IFN-
mRNA by approximately twofold (Fig. 4B, lanes 8 to 14, and Fig. 5A and B) relative to rtTA-expressing cells, indicating that wtI
B overexpression inhibited but did not completely block IFN-
mRNA expression. However, strikingly, in I
B
2N-expressing cells only low levels of IFN-
mRNA were detected at 12 and 16 h after infection (Fig. 4C, lanes 1 to 7), likely reflecting the leakiness of
transgene expression in these cells. Further induction of the I
B
-2N transgene with Dox treatment completely inhibited IFN-
mRNA expression (Fig. 4C, lanes 8 to 14, and Fig. 5C), resulting in an
almost 100-fold reduction in IFN-
mRNA levels. Similar low levels of
expression were also observed in I
B
-2N
4- and -2N+3C-expressing
cells with or without Dox addition (data not shown). IFN-
mRNA was
also induced in I
B
-expressing cells at 6 to 16 h after
Sendai virus infection (Fig. 4D, lanes 1 to 7); Dox induction of the
I
B
transgene resulted in a partial decrease of this gene
expression (Fig. 4D, lanes 8 to 14, and Fig. 5D).

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 4.
mRNA expression of IFN- in I B - and
I B -expressing cells after Sendai virus infection. (A) Total RNA
(5 µg) prepared from cells 0 to 48 h after Sendai virus
infection was used for RNase protection analysis with the human CK3
cytokine template set of the RiboQuant Multi-Probe RPA kit. Cells lines
are indicated at the top of each panel. Panels: A, rtTA-293 cells; B,
wtI B -expressing cells; C, I B -2N-expressing cells; D,
I B -expressing cells. Where indicated, the cells were pretreated
with Dox 48 h prior to Sendai virus infection. As a control, the
level of GAPDH is shown.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Quantification of IFN- mRNA expression.
Quantification of RNase protection autoradiographs was obtained by
normalizing values to the GAPDH and L32 (housekeeping gene) mRNA levels
and plotting the values as IFN- /GAPDH mRNA ratios. Panels: A,
rtTA-expressing cells; B, wtI B -expressing cells; C,
I B -2N-expressing cells; D, I B -expressing cells. Lightly
shaded columns, no Dox addition; darkly shaded columns, Dox addition (1 µg/ml) for 48 h.
|
|
IFN-
transcription is inhibited in I
B-expressing cells.
I
B-expressing 293 cells were transfected with IFN-
-CAT reporter
construct containing the IFN-
promoter from
281 to +19; at 24 h after transfection, cells were Sendai virus infected and analyzed at
48 h. Cells, either treated or not treated with Dox, showed the
same level of IFN-
-driven CAT activity, indicating that Dox itself
had no effect on IFN-
induction. However, IFN-
gene activity was
modulated significantly by Dox-induced transgene expression (Fig.
6). wtI
B
- and wtI
B
-
4
expressing cells showed a decrease in reporter gene activity after
Sendai virus infection, and this activity was reduced by one-half with
Dox addition. Also I
B
-2N- and I
B
-2N
4-expressing cells
displayed very low levels of gene activity, which was completely
inhibited after expression of the I
B
transgene. Finally, 293 cells expressing I
B
did not show a decrease in CAT activity after
Dox induction, despite induction of the I
B
transgene.


View larger version (61K):
[in this window]
[in a new window]
|
FIG. 6.
Inhibition of IFN- promoter activity in
I B-expressing 293 cells. IFN- -CAT reporter plasmid (2.5 µg)
was transfected into rtTA-293- and I B-expressing 293 cells by the
calcium phosphate method. After 24 h, cells were infected with
Sendai virus (500 HAU/ml) for 90 min as indicated. Cultures were
harvested at 48 h posttransfection, and 100 µg of the
cytoplasmic extracts was prepared from the various cell lines and
assayed for CAT activity for 4 h. As indicated, the cells were
treated or not treated with Dox 48 h before transfection. The CAT
activity observed with extracts of rtTA cells infected by Sendai virus
(20 to 30% acetylation) was taken as the 100% value.
|
|
Analysis of PRDII DNA binding activity in I
B-expressing
cells.
To correlate changes in gene activity with potential
changes in NF-
B-PRDII complex formation after virus infection,
mobility shift analyses were performed with nuclear extracts from
rtTA-293 and I
B-expressing cells (Fig.
7). Subunit composition of the protein-DNA complexes was determined with antibodies specific to p50,
p65, and c-Rel, since previous experiments demonstrated that these
three NF-
B subunits constituted the majority of NF-
B binding
activity on PRDII (17). The specificity of complex formation was controlled by competition with a 200-fold excess of unlabeled PRDII
oligonucleotide. For rtTA-293 cells, a specific complex appeared at 6 and at 16 h after Sendai virus infection. Anti-p50 and
anti-RelA(p65) antibodies resulted in a prominent shift-up of the
inducible complex, demonstrating that the lower complex represented the
NF-
B p50-p50 homodimer and the upper complex represented the p50-p65
heterodimer (Fig. 7A). With nuclear extracts from wtI
B-expressing
cells infected with Sendai virus, PRDII protein-DNA complex formation
corresponding to p50-p50 homodimers and p50-p65 heterodimers were
dramatically reduced in intensity and temporally delayed in appearance
until 16 h after infection (Fig. 7B). Similarly, in
I
B
-2N-expressing 293 cells, NF-
B complex formation was
inhibited and detected only at 16 h after Sendai virus infection
(Fig. 7C). With I
B
-expressing cells, formation of NF-
B-PRDII
complexes was only slightly reduced at 16 h after infection (Fig.
7D). These results demonstrate that I
B
expression interferes both
kinetically and quantitatively with the formation of NF-
B
protein-DNA complexes on the PRDII element of IFN-
promoter after
virus infection.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 7.
Analysis of PRDII DNA binding activity in
I B-expressing cells. Nuclear extracts were prepared from
rtTA-293-expressing (A), wtI B -expressing (B),
I B -2N-expressing (C), and I B -expressing (D) cells. Cells
were infected by Sendai virus (500 HAU/ml) and harvested at the times
indicated. Cells were treated with Dox at 48 h prior to Sendai
virus infection. Nuclear extracts were incubated in the presence of 5 µg of poly(dI-dC) for 20 min prior to the addition of radiolabelled
PRDII probe. For supershift experiments, NF- B-specific antisera
(31) were preincubated in presence of electrophoretic
mobility shift assay buffer and poly(dI-dC) prior to the addition of
the nuclear extracts.
|
|
 |
DISCUSSION |
In this study, the potential inhibitory effects of I
B
and
I
B
on IFN-
transcriptional activity were analyzed in transient transfections and in stable 293 cell lines expressing I
B transgenes under Tet-inducible control. In transient-transfection studies, high
levels of IFN-
-CAT reporter gene activity were produced after
Sendai virus infection, whereas overexpression of wtI
B
inhibited
IFN-
transcription in a dose-dependent manner. Overexpression of
different mutated forms of I
B
, particularly
I
B
-2N(S32A/S36A), completely blocked IFN-
transcription
even at low levels of basal expression. I
B
-3C and -
4 also
inhibited IFN-
transcription more dramatically than wtI
B
. In
contrast, I
B
was a poor inhibitor of IFN-
transcription,
indicating a minimal role for I
B
in the regulation of
NF-
B-dependent IFN-
gene expression. Similar results were
obtained by measuring IFN-
mRNA accumulation in Tet-inducible
rtTA-293 cells expressing the various I
B transgenes. The inhibition
of IFN-
transcription in I
B
- and I
B
-expressing cells
correlated directly with the delayed appearance of NF-
B-PRDII complex formation after Sendai virus infection. Overexpression of
I
B
or I
B
impaired NF-
B binding at an early stage of
infection, and the later appearance of NF-
B-PRDII complexes at
16 h in I
B
-expressing cells was not sufficient to restore
full IFN-
inducibility. Dox-inducible I
B
expression also
resulted in a slightly later appearance of NF-
B binding activity (16 h compared to 6 h in control cells) which decreased IFN-
expression moderately.
The IFN-
promoter contains multiple overlapping positive and
negative regulatory domains that bind specific members of the NF-
B,
IRF, and ATF transcription factor families in an induction-specific manner, together with the chromatin-associated HMGI(Y) proteins (reviewed in reference 20). Extensive work by the
Maniatis and Thanos groups revealed that virus-induced activation of
the IFN-
promoter is due to the assembly of a higher-order
transcription enhancer complex called an enhanceosome (15, 16, 24,
29, 40, 44). Transcriptional synergy involved in IFN-
activation also requires interaction of all transcription factor
activation domains with CBP/p300 (14, 21, 23, 29, 54). A
novel domain (aa 322 to 458), termed the synergism domain, was
identified in RelA; this domain contains a potential leucine zipper
domain present in CBP and CBP-interacting proteins. Through this
domain, RelA associates with CBP, and this interaction is essential for transcriptional synergy. The activation domains of the IFN-
transcription factors also interact with CBP in vivo and potentially
stabilize the initial association between RelA and CBP. Interestingly,
the enhanceosome is able to make contact with components of the basal transcription machinery in vitro (TFIID, TFIIA, TFIIB, and the USA
coactivator) (24). Based on these findings, it was proposed that synergistic activation of IFN-
initially involves simultaneous recruitment of RNA polymerase II and the basal transcriptional machinery by the enhanceosome via CBP recruitment by RelA, implicating CBP as a bridge between transcriptional machinery and the IFN-
enhancer. Consistent with the enhanceosome model, we were able to
interfere with IFN-
transcription in vivo by preventing the assembly
of the complete enhanceosome; continued sequestration of NF-
B in the
cytoplasm, particularly by the TD-I
B
forms, prevented formation
of the enhanceosome and activation of IFN-
transcription.
The Thanos group demonstrated that the I
B
inhibitory activity was
facilitated by the interaction of NF-
B with HMGI(Y), and a part of
their study was based on the analysis of complexes bound on a PRDII
probe (44). Our data are complementary with these
observations, and in the context of Sendai virus induction in 293 cells, I
B
does not appear to be involved in the control of
IFN-
transcription. A requirement for I
B
-regulated NF-
B activity may be unnecessary in the context of IFN-
activation because of the rapid and transient nature of IFN-
induction after virus infection. Together with other regulatory protein-DNA
interactions, IFN-
induction occurs within the first 6 to 12 h
of infection and then is rapidly repressed.
In response to induction by TNF-
or IL-1, the NF-
B-inducing
kinase activates the IKK complex that directly phosphorylates I
B
and I
B
at two amino-terminal serine residues, leading to I
B
and I
B
ubiquitination and subsequent degradation by the proteasome (36). It has recently been shown that other
IKK-associated proteins, such as NEMO/IKK
and IKAP, regulate the IKK
complex and are required for the activation by TNF-
or IL-1
(11, 34, 51). Mitogen-activated protein kinase kinase kinase
1 (MEKK1) has also been identified as an upstream regulator of the IKK
complex (30). HTLVI-Tax protein has recently been shown to
activate IKK
and IKK
, leading to NF-
B activation. Furthermore,
a dominant negative mutant of NIK blocked Tax induction of NF-
B,
thus implicating NIK as a critical upstream regulator (10, 18, 45,
52). Although many viruses induce NF-
B binding activity, this
study demonstrates for the first time the activation of the IKK complex by Sendai virus and the subsequent phosphorylation and degradation of
I
B
. Strikingly, the kinetics of the IKK activation by Sendai virus temporally reflect not only NF-
B induction but also
virus-induced activation of IFN-
mRNA synthesis. At present, the
involvement of upstream kinases in the phosphorylation of the IKK
complex by Sendai virus remains to be determined.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the Medical Research
Council of Canada. M.A. was supported by a FRSQ Santé fellowship, H.N. and C.H. were supported by FCAR studentships, and R.L. was supported by a Fraser, Monat, and McPherson Scholarship from McGill University. J.H. is a Senior Scientist of the Medical Research Council
of Canada.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Lady Davis
Institute for Medical Research, 3755 Cote Ste. Catherine, Montreal,
Quebec, Canada H3T1E2. Phone: (514) 340-8222, ext. 5265. Fax: (514)
340-7576. E-mail: mijh{at}musica.mcgill.ca.
 |
REFERENCES |
| 1.
|
Baldi, L.,
K. Brown,
G. Franzoso, and U. Siebenlist.
1996.
Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I B .
J. Biol. Chem.
271:376-379[Abstract/Free Full Text].
|
| 2.
|
Baldwin, A. S., Jr.
1996.
The NF- B and I B proteins: new discoveries and insights.
Annu. Rev. Immunol.
14:649-681[Medline].
|
| 3.
|
Beauparlant, P., and J. Hiscott.
1996.
Biological and biochemical inhibitors of the NF- B/Rel proteins and cytokine synthesis.
Cytokine Growth Factor Rev.
7:175-190[Medline].
|
| 4.
|
Beauparlant, P.,
H. Kwon,
M. Clarke,
R. Lin,
N. Sonenberg,
M. Wainberg, and J. Hiscott.
1996.
Transdominant mutants of I B block Tat-TNF synergistic activation of HIV-1 expression and virus multiplication.
J. Virol.
70:5777-5785[Abstract].
|
| 5.
|
Beauparlant, P.,
R. Lin, and J. Hiscott.
1996.
The role of the C-terminal domain of I B in protein degradation and stability.
J. Biol. Chem.
271:10690-10696[Abstract/Free Full Text].
|
| 6.
|
Brockman, J. A.,
D. C. Scherer,
T. A. McKinsey,
S. M. Hall,
X. Qi,
W. Y. Lee, and D. W. Ballard.
1995.
Coupling of a signal response domain in I B to multiple pathways for NF- B activation.
Mol. Cell. Biol.
15:2809-2818[Abstract].
|
| 7.
|
Brown, K.,
G. Franzoso,
L. Baldi,
L. Carlson,
L. Mills,
Y.-C. Lin,
S. Gerstberger, and U. Siebenlist.
1997.
The signal response of I B is regulated by transferable N- and C-terminal domains.
Mol. Cell. Biol.
17:3021-3027[Abstract].
|
| 8.
|
Brown, K.,
S. Gerstberger,
L. Carlson,
G. Franzoso, and U. Siebenlist.
1995.
Control of I B- proteolysis by site-specific, signal-induced phosphorylation.
Science
267:1485-1488[Abstract/Free Full Text].
|
| 9.
|
Chen, Z.,
J. Hagler,
V. J. Palombella,
F. Melandri,
D. Scherer,
D. Ballard, and T. Maniatis.
1995.
Signal-induced site-specific phosphorylation targets I B to the ubiquitin-proteasome pathway.
Genes Dev.
9:1586-1597[Abstract/Free Full Text].
|
| 10.
|
Chu, Z.-L.,
J. Didonato,
J. Hawiger, and D. W. Ballard.
1998.
The Tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates I B kinases containing IKK and IKK .
J. Biol. Chem.
273:15891-15894[Abstract/Free Full Text].
|
| 11.
|
Cohen, L.,
W. J. Henzel, and P. A. Baeuerle.
1998.
IKAP is a scaffold protein of the I B kinase complex.
Nature
395:292-296[Medline].
|
| 12.
|
DeLuca, C.,
H. J. Kwon,
N. Pelletier,
M. A. Wainberg, and J. Hiscott.
1998.
NF- B protects HIV-1 infected myeloid cells from apoptosis.
Virology
244:27-38[Medline].
|
| 13.
|
DiDonato, J. A.,
M. Hayakawa,
D. M. Rothwarf,
E. Zandi, and M. Karin.
1997.
A cytokine-responsive I B kinase that activates the transcription factor NF- B.
Nature
388:548-554[Medline].
|
| 14.
|
Eckner, R.
1996.
p300 and CBP as transcriptional regulators and targets of oncogenic events.
J. Biol. Chem.
377:685-688.
|
| 15.
|
Escalante, C. R.,
J. Yie,
D. Thanos, and A. K. Aggarwal.
1998.
Structure of IRF-1 with bound DNA reveals determinants of interferon regulation.
Nature
391:103-106[Medline].
|
| 16.
|
Falvo, J. V.,
D. Thanos, and T. Maniatis.
1995.
Reversal of intrinsic DNA bends in the IFN gene enhancer by transcription factors and the architectural protein HMG I(Y).
Cell
83:1101-1111[Medline].
|
| 17.
|
Garoufalis, E.,
I. Kwan,
R. Lin,
A. Mustafa,
N. Pepin,
A. Roulston,
J. Lacoste, and J. Hiscott.
1994.
Viral induction of the human interferon beta promoter: modulation of transcription by NF- B/Rel proteins and interferon regulatory factors.
J. Virol.
68:4707-4715[Abstract/Free Full Text].
|
| 18.
|
Geleziunas, R.,
S. Ferrell,
X. Lin,
Y. Mu,
E. Cunningham,
M. Grant, Jr.,
M. Connelly,
J. Hambor,
K. Marcu, and W. Greene.
1998.
Human T-cell leukemia virus type 1 Tax induction of NF- B involves activation of the I B kinase (IKK ) and IKK cellular kinases.
Mol. Cell. Biol.
18:5157-5165[Abstract/Free Full Text].
|
| 19.
|
Hirano, F.,
M. Chung,
H. Tanaka,
N. Maruyama,
I. Makino,
D. Moore, and C. Scheidereit.
1998.
Alternative splicing variants of I B establish differential NF- B signal responsiveness in human cells.
Mol. Cell. Biol.
18:2596-2607[Abstract/Free Full Text].
|
| 20.
|
Hiscott, J.,
H. Nguyen, and R. Lin.
1995.
Molecular mechanisms of interferon beta gene induction.
Sem. Virol.
6:161-173.
|
| 21.
|
Horvai, A. E.,
L. Xu,
E. Korzus,
G. Brard,
D. Kalafus,
T. M. Mullen,
D. W. Rose,
M. G. Rosenfeld, and C. K. Glass.
1997.
Nuclear integration of JAK/STAT and RAS/AP-1 signalling by CBP and p300.
Proc. Natl. Acad. Sci. USA
94:1074-1079[Abstract/Free Full Text].
|
| 22.
|
Jaffray, E.,
K. M. Wood, and R. T. Hay.
1995.
Domain organization of I B and the sites of interaction with NF- B p65.
Mol. Cell. Biol.
15:2166-2172[Abstract].
|
| 23.
|
Kee, B. L.,
J. Arias, and M. R. Montminy.
1996.
Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator.
J. Biol. Chem.
271:2373-2375[Abstract/Free Full Text].
|
| 24.
|
Kim, T. K., and T. Maniatis.
1998.
The mechanism of transcriptional synergy of an in vitro assembled interferon- enhanceosome.
Mol. Cell.
1:119-129.
|
| 25.
|
Kwon, H.,
N. Pelletier,
C. DeLuca,
P. Genin,
S. Cisternas,
R. Lin,
M. A. Wainberg, and J. Hiscott.
1998.
Inducible expression of I B repressor mutants interferes with NF- B activity and HIV-1 replication in Jurkat T cells.
J. Biol. Chem.
273:7431-7440[Abstract/Free Full Text].
|
| 26.
|
Lin, R.,
P. Beauparlant,
C. Makris,
S. Meloche, and J. Hiscott.
1996.
Phosphorylation of I B in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability.
Mol. Cell. Biol.
16:1401-1409[Abstract].
|
| 26a.
|
Lin, R.,
C. Heylbroeck,
P. M. Pitha, and J. Hiscott.
1998.
Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation.
Mol. Cell. Biol.
18:2986-2996[Abstract/Free Full Text].
|
| 27.
|
May, M. J., and S. Ghosh.
1998.
Signal transduction through NF- B.
Immunol. Today
19:80-88[Medline].
|
| 28.
|
Mercurio, F.,
H. Zhu,
B. W. Murray,
A. Shevchenko,
B. L. Bennett,
J. W. Li,
D. B. Young,
M. Barbosa, and M. Mann.
1997.
IKK-1 and IKK-2: cytokine-activated I B kinases essential for NF- B activation.
Science
278:860-866[Abstract/Free Full Text].
|
| 29.
|
Merika, M.,
A. J. Williams,
G. Chen,
T. Collins, and D. Thanos.
1998.
Recruitment of CBP/p300 by the IFN enhanceosome is required for synergistic activation of transcription.
Mol. Cell.
1:277-287[Medline].
|
| 30.
|
Nemoto, S.,
J. Didonato, and A. Lin.
1998.
Coordinate regulation of I B kinases by mitogen-activated protein kinase kinase kinase 1 and NF- B inducing kinases.
Mol. Cell. Biol.
18:7336-7343[Abstract/Free Full Text].
|
| 31.
|
Pepin, N.,
A. Roulston,
J. Lacoste,
R. Lin, and J. Hiscott.
1994.
Subcellular redistribution of HTLV-1-Tax protein by NF- B/Rel transcription factors.
Virology
204:706-716[Medline].
|
| 32.
|
Phillips, R. J., and S. Ghosh.
1997.
Regulation of I B in WEHI 231 mature B cells.
Mol. Cell. Biol.
17:4390-4396[Abstract].
|
| 33.
|
Rodriguez, M. S.,
I. Michalopoulos,
F. Arenzana-Seisdedos, and R. T. Hay.
1995.
Inducible degradation of I B in vitro and in vivo requires the acidic C-terminal domain of the protein.
Mol. Cell. Biol.
15:2413-2419[Abstract].
|
| 34.
|
Rothwarf, D. M.,
E. Zandi,
G. Natoli, and M. Karin.
1998.
IKK- is an essential regulatory subunit of the I B kinase complex.
Nature
395:297-300[Medline].
|
| 35.
|
Régnier, C.,
H. Y. Song,
X. Gao,
D. V. Goeddel,
Z. Cao, and M. Rothe.
1997.
Identification and characterization of an I B kinase.
Cell
90:373-383[Medline].
|
| 36.
|
Scheidereit, C.
1998.
Docking I B kinases.
Nature
395:225-226[Medline].
|
| 37.
|
Scherer, D. C.,
J. A. Brockman,
Z. Chen,
T. Maniatis, and D. W. Ballard.
1995.
Signal-induced degradation of I B requires site-specific ubiquitination.
Proc. Natl. Acad. Sci. USA
92:11259-11263[Abstract/Free Full Text].
|
| 38.
|
Schwarz, E.,
D. Antwerp, and I. Verma.
1996.
Constitutive phosphorylation of I B by casein kinase II occurs preferentially at serine 293: requirement for degradation of free I B .
Mol. Cell. Biol.
16:3554-3559[Abstract].
|
| 39.
|
Suyang, H.,
R. Phillips,
I. Douglas, and S. Ghosh.
1996.
Role of unphosphorylated, newly synthesized I B in persistent activation of NF- B.
Mol. Cell. Biol.
16:5444-5449[Abstract].
|
| 40.
|
Thanos, D., and T. Maniatis.
1995.
Virus induction of human IFN gene expression requires the assembly of an enhanceosome.
Cell
83:1091-1100[Medline].
|
| 41.
|
Thompson, J. E.,
R. J. Phillips,
H. Erdjument-Bromage,
P. Tempst, and S. Ghosh.
1995.
I B- regulates the persistent response in a biphasic activation of NF- B.
Cell
80:573-582[Medline].
|
| 42.
|
Traenckner, E. B.,
H. L. Phal,
T. Henkel,
N. K. Schmidt,
S. Wilk, and P. A. Baeuerle.
1995.
Phosphorylation of human I B on serines 32 and 36 controls I B proteolysis and NF- B activation in response to diverse stimuli.
EMBO J.
14:2876-2883[Medline].
|
| 43.
|
Traenckner, E. B. M.,
H. L. Pahl,
T. Henkel,
K. N. Schmidt,
S. Wilk, and P. A. Baeuerle.
1995.
Phosphorylation of human I B on serines 32 and 36 controls I B proteolysis and NF- B activation in response to diverse stimuli.
EMBO J.
14:2876-2883.
|
| 44.
|
Tran, K.,
M. Merika, and D. Thanos.
1997.
Distinct functional properties of I B and I B .
Mol. Cell. Biol.
17:5386-5399[Abstract].
|
| 45.
|
Uhlik, M.,
L. Good,
G. Xiao,
E. Harhaj,
E. Zandi,
M. Karin, and S.-C. Sun.
1998.
NF- B-inducing kinase and I B kinase participate in human T-cell leukemia virus 1 Tax-mediated NF- B activation.
J. Biol. Chem.
273:21132-21136[Abstract/Free Full Text].
|
| 46.
|
Verma, I. M.,
J. K. Stevenson,
E. M. Schwarz,
D. V. Antwerp, and S. Miyamoto.
1995.
Rel/NF- B/I B family: intimate tales of association and dissociation.
Genes Dev.
9:2723-2735[Free Full Text].
|
| 47.
|
Vilcek, J., and G. Sen.
1996.
Interferons and other cytokines, p. 375-399.
In
B. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven, New York, N.Y.
|
| 48.
|
Wathelet, M. G.,
C. H. Lin,
B. S. Parakh,
L. V. Ronco,
P. M. Howley, and T. Maniatis.
1998.
Virus infection induces the assembly of coordinately activated transcription factors on the IFN- enhancer in vivo.
Mol. Cell.
1:507-518[Medline].
|
| 49.
|
Weil, R.,
C. Laurent-Winter, and A. Israel.
1997.
Regulation of I B degradation. Similarities to and differences from I B .
J. Biol. Chem.
272:9942-9949[Abstract/Free Full Text].
|
| 50.
|
Woronicz, J. D.,
X. Gao,
Z. Cao,
M. Rothe, and D. V. Goeddel.
1997.
I B kinase- : NF- B activation and complex formation with I B kinase- and NIK.
Science
278:866-869[Abstract/Free Full Text].
|
| 51.
|
Yamaoka, S.,
G. Courtois,
C. Bessia,
S. T. Whiteside,
R. Weil,
F. Agou,
H. E. Kirk,
R. J. Kay, and A. Israel.
1998.
Complementation cloning of NEMO, a component of the I B kinase complex essential for NF- B activation.
Cell
93:1231-1240[Medline].
|
| 52.
|
Yin, M.-J.,
L. B. Christerson,
Y. Yamamoto,
Y.-T. Kwak,
S. Xu,
F. Mercurio,
M. Barbosa,
M. H. Cobb, and R. B. Gaynor.
1998.
HTLV-I Tax protein binds to MEKK1 to stimulate I B kinase activity and NF- B activation.
Cell
93:875-884[Medline].
|
| 53.
|
Zandi, E.,
D. M. Rothwarf,
M. Delhase,
M. Hayakawa, and M. Karin.
1997.
The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation.
Cell
91:243-252[Medline].
|
| 54.
|
Zhang, J. J.,
U. Vinkemeier,
W. Gu,
D. Chakravarti,
C. M. Horvath, and J. E. Darnell.
1996.
Two contact regions between STAT1 and CBP/p300 in interferon gamma signalling.
Proc. Natl. Acad. Sci. USA
93:15092-15096[Abstract/Free Full Text].
|
Journal of Virology, April 1999, p. 2694-2702, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Konrad, A., Wies, E., Thurau, M., Marquardt, G., Naschberger, E., Hentschel, S., Jochmann, R., Schulz, T. F., Erfle, H., Brors, B., Lausen, B., Neipel, F., Sturzl, M.
(2009). A Systems Biology Approach To Identify the Combination Effects of Human Herpesvirus 8 Genes on NF-{kappa}B Activation. J. Virol.
83: 2563-2574
[Abstract]
[Full Text]
-
Jiao, P., Tian, G., Li, Y., Deng, G., Jiang, Y., Liu, C., Liu, W., Bu, Z., Kawaoka, Y., Chen, H.
(2008). A Single-Amino-Acid Substitution in the NS1 Protein Changes the Pathogenicity of H5N1 Avian Influenza Viruses in Mice. J. Virol.
82: 1146-1154
[Abstract]
[Full Text]
-
Nogalski, M. T., Podduturi, J. P., DeMeritt, I. B., Milford, L. E., Yurochko, A. D.
(2007). The Human Cytomegalovirus Virion Possesses an Activated Casein Kinase II That Allows for the Rapid Phosphorylation of the Inhibitor of NF-{kappa}B, I{kappa}B{alpha}. J. Virol.
81: 5305-5314
[Abstract]
[Full Text]
-
Taylor, R. T., Bresnahan, W. A.
(2006). Human Cytomegalovirus IE86 Attenuates Virus- and Tumor Necrosis Factor Alpha-Induced NF{kappa}B-Dependent Gene Expression.. J. Virol.
80: 10763-10771
[Abstract]
[Full Text]
-
Recklies, A. D., Ling, H., White, C., Bernier, S. M.
(2005). Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes. J. Biol. Chem.
280: 41213-41221
[Abstract]
[Full Text]
-
Grimm, T., Schneider, S., Naschberger, E., Huber, J., Guenzi, E., Kieser, A., Reitmeir, P., Schulz, T. F., Morris, C. A., Sturzl, M.
(2005). EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood
105: 3263-3269
[Abstract]
[Full Text]
-
Elco, C. P., Guenther, J. M., Williams, B. R. G., Sen, G. C.
(2005). Analysis of Genes Induced by Sendai Virus Infection of Mutant Cell Lines Reveals Essential Roles of Interferon Regulatory Factor 3, NF-{kappa}B, and Interferon but Not Toll-Like Receptor 3. J. Virol.
79: 3920-3929
[Abstract]
[Full Text]
-
Andreakos, E., Smith, C., Monaco, C., Brennan, F. M., Foxwell, B. M., Feldmann, M.
(2003). Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood
101: 983-991
[Abstract]
[Full Text]
-
Sakaue, G., Hiroi, T., Nakagawa, Y., Someya, K., Iwatani, K., Sawa, Y., Takahashi, H., Honda, M., Kunisawa, J., Kiyono, H.
(2003). HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses. J. Immunol.
170: 495-502
[Abstract]
[Full Text]
-
Wang, X., Li, M., Zheng, H., Muster, T., Palese, P., Beg, A. A., García-Sastre, A.
(2000). Influenza A Virus NS1 Protein Prevents Activation of NF-kappa B and Induction of Alpha/Beta Interferon. J. Virol.
74: 11566-11573
[Abstract]
[Full Text]
-
Genin, P., Algarte, M., Roof, P., Lin, R., Hiscott, J.
(2000). Regulation of RANTES Chemokine Gene Expression Requires Cooperativity Between NF-{kappa}B and IFN-Regulatory Factor Transcription Factors. J. Immunol.
164: 5352-5361
[Abstract]
[Full Text]